| Previous close | 0.80 |
| Open | 0.80 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | 3,154,521 |
| Avg. volume | 6,414,545 |
| Market cap | 21.16M |
| Beta | N/A |
| PE ratio (TTM) | -∞ |
| EPS (TTM) | -0 |
| Earnings date | N/A |
| Dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.02 |
- PR Newswire•10 months ago
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) From CRT Pioneer Fund, UK
PNT737 is being investigated in two recently initiated Phase 1 clinical trials, currently sponsored and managed by the Cancer Research UK Centre for Drug Development, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.
We're sorry, but this is all we were able to find on this topic.
